TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: Evidence from an updated meta-analysis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Peng, Qiliu ^a   Lao, Xianjun ^a   Chen, Zhiping ^b   Lai, Hao ^b   Deng, Yan ^a   Wang, Jian ^a   Mo, Cuiju ^a   Sui, Jingzhe ^a   Wu, Junrong ^a   Zhai, Limin ^a   Yang, Shi ^a   Qin, Xue ^a   Li, Shan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN;

AFRICAN AMERICAN; ARTICLE; ASIAN; CANCER RISK; CAUCASIAN; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS HEPATITIS; CONFIDENCE INTERVAL; EPISTASIS; ETHNIC GROUP; GENETIC PREDISPOSITION; GENETICS; LIVER TUMOR; META ANALYSIS; PUBLISHING; RISK; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; CONFIDENCE INTERVALS; EPISTASIS, GENETIC; ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; PUBLICATION BIAS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893506200     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082773     Document Type: Article

References (56)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Li Q, Du J, Guan P, Qu CF, Dai M (2012) [Estimation and prediction of incidence, mortality and prevalence on liver cancer, in 2008, China]. Zhonghua Liu Xing Bing Xue Za Zhi 33: 554-557.
3. El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27-34.
4. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
5. Dragani TA (2010) Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 52: 252-257.
6. Tong WM, Hande MP, Lansdorp PM, Wang ZQ (2001) DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression. Mol Cell Biol 21: 4046-4054.
7. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, et al. (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460: 1132-1135.
8. Marte B (2002) Cancer: super p53. Nature 420: 279.
9. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, et al. (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38: 1133-1141.
10. Orsted DD, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG (2007) Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 204: 1295-1301.
11. Siddique M, Sabapathy K (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500.
12. Bond GL, Hu W, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8.
13. Ma HB, Huang T, Han F, Chen WY (2012) Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk - a meta-analysis. Asian Pac J Cancer Prev 13: 2841-2846.
14. Tomoda T, Nouso K, Sakai A, Ouchida M, Kobayashi S, et al. (2012) Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. J Gastroenterol Hepatol 27: 797-804.
15. Yang Y, Xia T, Li N, Zhang J, Cong W, et al. (2013) Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell 4: 71-81.
16. Jiang D (2008) P53 gene mutation, P53 R72P and MDM2 SNP309 polymorphisms and hepatocellular carcinoma development and prognosis. 4: 1-123.
17. Lv L, Wang P, Zhou X, Sun B (2013) Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol 34: 1451-1459.
18. Ding C, Yu H, Qin H (2012) TP53 codon 72 polymorphism with hepatocellular carcinoma: a metaanalysis. J Int Med Res 40: 446-454.
19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
20. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, et al. (2005) Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162: 201-211.
21. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
23. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
24. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
25. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
26. Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ, et al. (2005) A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett 229: 77-83.
27. Zhu ZZ, Cong WM, Zhu GS, Liu SF, Xian ZH, et al. (2005) [Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in Chinese population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22: 632-635.
28. Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, et al. (2007) The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res 37: 748-754.
29. Akkiz H, Sumbul AT, Bayram S, Bekar A, Akgollu E (2010) MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol 34: 448-452.
30. Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, et al. (2009) Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol 15: 5592-5597.
31. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, et al. (2006) MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12: 4867-4871.
32. Ezzikouri S, Essaid El Feydi A, Afifi R, Benazzouz M, Hassar M, et al. (2011) Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma. Int J Biol Markers 26: 229-233.
33. Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, et al. (2011) TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer 6: 13.
34. Wang X, Zhang X, Qiu B, Tang Y, Sun H, et al. (2012) MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int 32: 1172-1178.
35. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, et al. (2008) MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29: 1192-1196.
36. Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, et al. (2012) p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study. Mol Biol Rep 39: 1639-1647.
37. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, et al. (2004) Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett 208: 75-79.
38. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, et al. (1999) A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 29: 697-702.
39. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, et al. (2003) Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 193: 199-205.
40. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, et al. (2011) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128: 412-417.
41. Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, et al. (2013) Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene 524: 156-160.
42. Zhang Y, Fan X, Yu H (2012) Association of p53 Codon72 Polymorphism and Risk of Hepatocellular Carcinoma. 4: 189-193.
43. Peng T, Yan L, Liu Z, Shen H, Choon N, et al. (2004) Guangxi hepatocellular carcinoma is associated with P53 codon 72 polymorphism. 4: 313-315.
44. Meek DW (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723.
45. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, et al. (2005) A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 280: 26776-26787.
46. Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468.
47. Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65: 5481-5484.
48. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
49. Hong Y, Miao X, Zhang X, Ding F, Luo A, et al. (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65: 9582-9587.
50. Chan HL, Sung JJ (2006) Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 26: 153-161.
51. Castello G, Costantini S, Scala S (2010) Targeting the inflammation in HCVassociated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med 8: 109.
52. Chen J, Wu X, Lin J, Levine AJ (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445-2452.
53. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, et al. (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27: 110-117.
54. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. (2007) MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 120: 563-565.
55. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119: 718-721.
56. Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335: 914-916.